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Abstract
Background: The current standard practice of lung lesion diagnosis often leads to inconclusive results, requiring
additional diagnostic follow up procedures that are invasive and often unnecessary due to the high benign rate in
such lesions (Chest 143:e78S-e92, 2013). The Percepta bronchial genomic classifier was developed and clinically
validated to provide more accurate classification of lung nodules and lesions that are inconclusive by bronchoscopy,
using bronchial brushing specimens (N Engl J Med 373:243–51, 2015, BMC Med Genomics 8:18, 2015). The analytical
performance of the Percepta test is reported here.
Methods: Analytical performance studies were designed to characterize the stability of RNA in bronchial brushing
specimens during collection and shipment; analytical sensitivity defined as input RNA mass; analytical specificity
(i.e. potentially interfering substances) as tested on blood and genomic DNA; and assay performance studies including
intra-run, inter-run, and inter-laboratory reproducibility.
Results: RNA content within bronchial brushing specimens preserved in RNAprotect is stable for up to 20 days at
4 °C with no changes in RNA yield or integrity. Analytical sensitivity studies demonstrated tolerance to variation in RNA
input (157 ng to 243 ng). Analytical specificity studies utilizing cancer positive and cancer negative samples mixed with
either blood (up to 10 % input mass) or genomic DNA (up to 10 % input mass) demonstrated no assay interference.
The test is reproducible from RNA extraction through to Percepta test result, including variation across operators, runs,
reagent lots, and laboratories (standard deviation of 0.26 for scores on > 6 unit scale).
Conclusions: Analytical sensitivity, analytical specificity and robustness of the Percepta test were successfully verified,
supporting its suitability for clinical use.
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Background
Lung cancer has the highest mortality of all malignancies
with approximately 160,000 deaths per year in the U.S.
and a 5-year survival rate of only 17 % [1]. The majority
of lung cancers are diagnosed at an advanced stage, al-
though it has been reported that detection at an early
stage leads to improved survival. Recommendations call
for subjects with a positive radiological imaging finding
to be managed according to the likelihood of malignancy
[2], with low risk subjects referred for radiological sur-
veillance and intermediate to high risk subjects referred
for biopsy procedures. Bronchoscopy is considered the
safest biopsy approach and it is estimated that 500,000
bronchoscopies are performed per year in the U.S. [3],
of which roughly half are for the diagnosis of lung can-
cer. However the clinical sensitivity of bronchoscopy is
imperfect, particularly with small and peripheral suspi-
cious lesions [4].
It has been shown that exposure to tobacco smoke alters
gene expression in airway epithelial cells [5, 6], and that a
subset of genes are altered irreversibly [7], establishing a
basis for diagnosing smoking related diseases. Subsequent
studies showed that gene expression profiling of epithelial
cells collected from the main stem bronchus during bron-
choscopy can improve the sensitivity of bronchoscopy [8],
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and more recently using a similar approach, a bronchial
genomic classifier (Percepta®) has been validated in large,
multicenter, prospective trials [9, 10]. The Percepta test re-
lies on collection of bronchial epithelial cells from a nor-
mal appearing area of the mainstem bronchus from
subjects undergoing bronchoscopy for suspicion of lung
cancer. The test was shown to have a negative predictive
value of 91 % with intermediate risk patients and 100 %
with low risk patients [9, 10]. The potential utility of the
test is therefore to avoid unnecessary invasive diagnostic
procedures (such as transthoracic needle biopsy or surgi-
cal lung biopsy) and the associated complications when
bronchoscopy is inconclusive in patients with benign dis-
ease [11, 12].
While the clinical validity of the Percepta test has been
demonstrated in independent studies [9, 10], it is equally
important to demonstrate analytic validity of this newly-
developed molecular test. The Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) Working
Group and the Centers for Disease Control’s ACCE Project
(Analytic validity, Clinical validity, Clinical utility and asso-
ciated Ethical, legal and social implications) have defined
parameters which should be used to evaluate analytical val-
idity of novel genomic tests [13, 14]. Here we report the re-
sults of recommended studies designed to test the
analytical performance of the Percepta test. Studies in-
cluded evaluation of specimen stability during collection,
shipment and storage, analytical sensitivity to input RNA
quantity, analytical specificity in response to contaminating
blood and genomic DNA, and several reproducibility stud-
ies (intra- and inter-assay, and inter-laboratory), demon-
strating robustness to changes across a range of technical
variables. Quality control recommendations were exten-
sively implemented and verified via the use of control mate-




Normal appearing bronchial epithelial cells (BEC) were
collected from the mainstem bronchus using standard cy-
tology brushes during AEGIS 1 and AEGIS 2, two pro-
spective, multicenter, observational studies (NCT01309087
and NCT00746759). The enrolled patients had already been
referred for bronchoscopy examinations as part of their
clinical care for suspicion of lung cancer. Following sample
collection, brushes were immediately clipped and sub-
merged in RNAprotect preservative solution (QIAGEN,
Valencia, CA) post-collection. Samples were stored at 2–
8 °C before being shipped in a NanoCool shipper (Nano-
Cool, Albuquerque, NM) with active cooling to 2–8 °C,
and stored at 2–8 °C upon receipt prior to RNA extraction.
Fresh peripheral blood samples were collected from
healthy voluntary participants. Immediately after collection,
the blood samples were mixed with the RNAprotect preser-
vative at a 1:5 ratio as recommended by the manufacturer.
Subsequently, the pure blood samples were tested following
the Percepta molecular test lab procedure as outlined below
from total RNA extraction to array results.
Ethics approval was obtained prior to the initiation of
the studies described in this report. To characterize ana-
lytical performances of the assay, we used total RNA sam-
ples (anonymously with no Protected Health Information)
that were derived from human bronchial epithelial cell
specimens. These total RNA samples were already avail-
able from previously registered clinical trials which were
published as clinical validation studies [9, 10]. Addition-
ally, we have obtained ethics approval from the Liberty
IRB and informed consents from all participants for the
use of the freshly collected blood samples.
RNA extraction, amplification, and microarray
hybridization
The Percepta molecular test lab procedure starts with the
extraction of total RNA from bronchial brushing speci-
mens using the miRNeasy Kit (QIAGEN, Valencia, CA).
Yield was measured using NanoDrop 8000 instruments
(NanoDrop, Wilmington, DE) and quality was measured
by the RNA Integrity Number (RIN) generated by the
BioAnalyzer System (Agilent Technologies, Santa Clara,
CA). Samples with concentration <21 ng/μL and/or RIN
<4 were stopped from further processing per pre-specified
QC criteria. Positive (lung tissue lysate) and negative
(water) controls were developed and used as applicable
with pre-defined RNA yield and quality acceptance criteria
to ensure the reliability of the procedure. For each sample,
200 ng of total RNA were amplified using the Ambion
WT Expression Kit (Life Technologies, Carlsbad, CA),
fragmented and labeled using the Affymetrix WT Labeling
and Controls Kit (Affymetrix, Santa Clara, CA), followed
by overnight hybridization of 2.75 μg biotin-labeled cDNA
to a Gene 1.0 ST microarray (Affymetrix). The arrays were
then washed, stained, and scanned on a GeneChip System
GCS3000 or DXv2 (Affymetrix) following manufacturer’s
protocols. Cancer positive and cancer negative total RNA
controls were included in each sample batch starting from
the amplification step. Pre-defined specifications for yield,
quality, and Percepta classification of these control sam-
ples were used as batch acceptance criteria.
Genomic DNA analysis
To evaluate the genomic DNA amount present in the
total RNA samples, the Quantifast SYBR Green PCR kit
was used following manufacturer’s protocol (QIAGEN,
Valencia, CA), using a normalized 50 ng total RNA input
for the test samples.
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Data analysis
All data analysis was done in R version 3.1.2 [15]. To
obtain a Percepta test result, transcript signal inten-
sities for each array were first normalized using fro-
zen robust multi-array analysis (fRMA) [16]. The
Percepta calls (two-class calls based on a locked score
decision boundary) and scores were subsequently de-
rived using 23 genes and the patient age following
the classifier algorithm as described [10]. Note that in
the previous study [10], the Percepta classifier score
refers to a prediction from logistic regression which
returns predicted probabilities of lung cancer within a
range of 0 to 1. In this report, a logit transform was
applied to the scores so that their range would be ap-
propriate for linear model fits in the statistical ana-
lyses that follow. This is explained in greater detail in
Additional file 1.
Brushing sample stability was established using an
ANOVA test of means of yield and failure rates of
RIN over time. Linear mixed effect models were used
to evaluate the effects of RNA input amount, blood
interference, and genomic DNA interference at the
5 % significance level. To claim that a variable was
not statistically significant, its p-value had to be
>0.05 under all attempted models, and the lowest p-
value was reported so that lack of significance was
ensured for all models fit. Transcript signal intensity
Pearson correlations between arrays from different
test sample groups were calculated from the genes
used in the algorithm. All 95 % confidence intervals
for standard deviations (SD) were obtained by boot-
strap where the residuals of a linear mixed-effects
model controlling for sample and other sources of
variation (depending on the type of SD reported)
were sampled with replacement to create a bootstrap
sample. The distribution of blood contamination level
in the total RNA from the AEGIS clinical samples
was simulated based on 1) the observed blood con-
tamination levels based on a predefined color scale,
2) the mass variation of pure fresh blood derived
total RNA, and 3) the mass variation of total RNA
from the clinical samples, assuming these three fac-
tors contribute to the blood contamination level in-
dependently. The simulation to assess the maximum
tolerable level of variation in Percepta scores was
performed by making multiple random draws from a
normal distribution for each AEGIS sample, with the
mean defined as the Percepta score obtained during
the clinical validation [9, 10] and the SD at each spe-
cified level. The resulting average performance from
all draws (each draw across all samples) at a given
SD level were evaluated for sensitivity, specificity,
NPV and PPV. Further details of the data analysis
can be found in Additional file 1.
Results
Control materials
Multiple lots of lung tissue lysate were manufactured (at
Veracyte) and used as process controls during RNA ex-
traction. Three different lots of controls were tested over
several weeks of independent runs with 7 replicates of
each lot per run, by two different operators. Testing of
three lots is standard practice to verify the reproducibil-
ity of a manufacturing or laboratory process. Lung lysate
controls consistently produced the expected quantity
and quality of total RNA, resulting in within-lot coeffi-
cients of variation (CV) ranging from 4 to 6 % for yield
and 2–4 % for RIN (data not shown).
Similarly, multiple lots of cancer positive and cancer
negative total RNA were manufactured (at Veracyte) and
tested for their use as process controls for amplification
and hybridization steps. The reproducible Percepta results
obtained from these controls enabled concurrent monitor-
ing of assay performance for each run. All Percepta tests
and studies outlined below included at least one cancer
positive and one cancer negative total RNA controls.
Bronchial brushing specimen stability
To demonstrate the cumulative stability of the RNA
content within the preserved BEC samples under the
typical collection and storage conditions, comprehensive
sample tracking data were collected from AEGIS sam-
ples and the stability was evaluated using metrics of
RNA yield and integrity. The length of time from sample
collection till RNA extraction was accounted for. With
the pre-specified sample quality criteria, no statistically sig-
nificant difference was observed among samples with a cu-
mulative 2–8 °C storage time of up to 20 days based on
RIN failure rate (p = 0.148, Fig. 1a) or RNA yield (p = 0.955,
Fig. 1b). Combined with the manufacturer’s recommended
2–8 °C storage of up to 4 weeks, these data strongly sup-
port the sample storage stability in RNAprotect at 2–8 °C
at the clinical site and testing lab and shipping in chilled
box for routine practice.
Analytical sensitivity - total RNA input quantity
While the standard total RNA input quantity to the
Percepta assay is fixed (200 ng), concentration measure-
ment (by NanoDrop) and pipetting (using Rainin LTS
pipets) variability around this nominal input amount are
expected in routine practice. Therefore, a study was per-
formed to characterize the transcript array signal inten-
sities and Percepta results relative to variability in total
RNA input quantity. Based on the manufacturers’ speci-
fications in concentration measurement and pipetting,
the standard deviation (SD) of such variation translates
to 15.2 ng, given the intended 200 ng input. Therefore,
the titration levels were designed to be 200 ng ± 30 ng
(corresponding to ± 1.96 SD, covering 95 % of the
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samples) and 200 ng ± 43 ng (corresponding to ± 2.81
SD, covering 99.5 % of the samples). Total RNA from a
cancer positive and a cancer negative bronchial brushing
sample were processed in triplicate through the Percepta
test at the designed total RNA input levels (157, 170,
200, 230 and 243 ng). As shown in Fig. 2a, Percepta
scores for each sample did not differ significantly with
RNA input when evaluated with a linear mixed effect
model (p-value = 0.69). The transcript signal intensities
of each sample were equally highly correlated within
each single group of RNA input (Pearson R2 coefficients
0.986–0.998, with a mean of 0.992) and between the test
input groups and the baseline 200 ng condition (R2 coef-
ficients 0.982–0.998, with a mean of 0.992). Overall, this
study demonstrated highly robust analytical sensitivity of
the Percepta test to RNA input quantity variation within
the tested range.
Analytical specificity - blood
Occasionally, bronchial brushing samples may contain
small amounts of blood due to variation in the collection
procedure or to individual patients. This was confirmed
by the visual inspection of samples collected during the
AEGIS trials, which showed that greater than 80 % of
the samples have no visible blood contamination. The
procedure to collect BEC specimens limits the volume
of contaminating blood using standard sheathed cy-
tology brushes (Additional file 1). Further, a simulation
of the distribution of blood contamination levels in the
total RNA from the clinical samples showed that <1 %
of the clinical samples have >1 % of blood derived RNA,
with the most extreme cases have ~10 % of blood de-
rived RNA (Additional file 1). To experimentally test the
impact of blood on the Percepta results, in vitro mix-
tures were created using RNA from one cancer positive
or one cancer negative brushing sample that were each
spiked with the total RNA derived from a fresh whole
blood sample, while maintaining the combined total
RNA input mass at 200 ng. Figure 2b shows that when 5
and 10 % of blood derived total RNA were spiked into
the brushing derived RNA samples and tested in tripli-
cates via the Percepta test, no score shifts were observed
compared to 0 % blood (p-value = 0.515), supporting that
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Fig. 1 Bronchial brushing specimen stability at 2–8 °C in RNAprotect. All samples from the AEGIS 1 and 2 clinical studies were analyzed at the
time of RNA extraction. The resulting QC data were plotted as a function of the cumulative total storage time at 2–8 °C. The number of samples in
each time window (n) for both RIN and yield is shown at the top. a RIN failure rate. Black dots: observed values. Vertical lines: 95 % CI. b Boxplots of
total RNA yield
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Analytical specificity – genomic DNA
Genomic DNA was tested as a potentially interfering
substance, as presence of DNA can occur from inadvert-
ent variation or deviations from the RNA extraction
process. To assess the extent of genomic DNA contam-
ination, a qPCR based genomic DNA quantitation assay
was used. A set of planned RNA extraction procedural
deviation tests revealed that excessive genomic DNA
carryover was only observed when chloroform was omit-
ted in the procedure, which was a visually detectable de-
viation. For all other deviation conditions tested, the
observed genomic DNA levels in the RNA samples were
consistently 1 % or less. Similarly, the levels of contam-
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Fig. 2 Analytical sensitivity and specificity of the Percepta test. The y-axes are on a relative scale, with 0 representing the mean of each sample
across all input levels (mean centered). Sample A and C are cancer negative. Sample B is cancer positive. Each box represents test results from
technical triplicates. a Effect of input mass variation on Percepta score. b Analytical specificity of the Percepta test against blood. The x-axis shows
the percentage of total input mass, fixed at 200 ng, from the blood. c Analytical specificity of the Percepta test against genomic DNA. The x-axis
shows the percentage of total input mass, fixed at 200 ng, from genomic DNA
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were also found to be consistently <1 % (data not
shown). Thus, assay testing was designed for up to 10 %
genomic DNA contamination as a worst-case scenario
(10 times above baseline). One cancer positive and one
cancer negative brushing sample that were tested to
have < 1 % genomic DNA were spiked with 1, 5 and
10 % additional genomic DNA and tested via Percepta in
triplicate per condition. There was no significant differ-
ence in the Percepta score between samples with up to
10 % genomic DNA and samples with no additional gen-
omic DNA spiked in (p-value = 0.20) (Fig. 2c). This study
demonstrated that the Percepta test is not affected by
genomic DNA at the levels encountered in clinical
samples.
Assay reproducibility
In order to assess the maximum tolerable level of vari-
ation in Percepta scores, a simulation study was per-
formed by adding increasing levels of random variation
in silico to the original Percepta scores obtained from
the validation samples [9]. The resulting Negative Pre-
dictive Value (NPV) was evaluated since the Percepta
test is designed to be a high sensitivity (rule-out) test.
The simulation demonstrated that the Percepta scores
can tolerate a standard deviation of up to 0.4 units on a
roughly 6-point scale in order to maintain an NPV of
90 % (Additional file 1).
The within-run and inter-run reproducibility of the
Percepta test were evaluated using total RNA from 10
bronchial brushing samples with high, medium and low
scores, and 6 control samples, processed in triplicate in
three experimental runs (144 Percepta results), varying
reagent lots, operators, and days (spanning three weeks).
The pooled within-run SD of Percepta scores was
estimated to be 0.222 (95 % CI 0.186 to 0.257; Fig. 3). The
transcript signal intensities from within-run replicates had
mean R2 coefficients of 0.985 (range 0.945 to 0.998).
Additionally, the Percepta scores were estimated to
have an inter-run pooled SD of 0.259 (95 % CI 0.217 to
0.304; Fig. 3) across all samples in this study. When rep-
licates were pooled across runs, all brushing samples
and total RNA control samples had standard deviations
below the aforementioned tolerance of 0.4 units (range
0.082 to 0.340). The transcript signal intensities from
across-run replicates had mean R2 coefficients of 0.983
(range 0.933 to 0.998). Thus, the Percepta test demon-
strated sufficiently high reproducibility across reagent
lots, operators, and processing runs. In contrast, the
inter-class score SD was estimated to be 1.180 (95 % CI
1.115–1.246), which includes biological variation be-
tween cancer and non-cancer samples from the AEGIS 1
and 2 clinical studies.
Inter-laboratory reproducibility
Total RNA from 22 different patient bronchial brushing
samples was processed using the Percepta test in the la-
boratory where the test was developed (Veracyte Research
& Development Laboratory). A second aliquot of RNA
from the same samples was later tested in a different,
CLIA-certified reference laboratory using different opera-
tors, reagent lots, and equipment (same model equipment,
different by serial number; Veracyte CLIA laboratory).
The Percepta calls for all samples were 100 % concordant
between the two laboratories. Further, the Percepta scores
of the 22 samples between the two laboratories are highly
correlated (R2 = 0.992), demonstrating inter-laboratory re-
producibility and accuracy of Percepta results. Inter-

















Inter−class Inter−lab Inter−run Intra−run
Observed
values: 1.180 0.276 0.259 0.222
n: 938 44 144 144
Biological variation Technical variation
Fig. 3 Comparison of Percepta score variability. The inter-class score SD includes biological variation between cancer and non-cancer samples
and was computed from all samples passing quality control criteria from the AEGIS 1 and 2 clinical studies. Dashed line: the maximum tolerable
level of variation in Percepta scores derived from simulation. Black dots: observed values. Vertical lines: 95 % CI. The number of data points used
to calculate each SD (n) is shown at the top
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was estimated to be 0.276 (95 % CI 0.172–0.389),
which is in agreement with the SD of 0.259
calculated for within-lab inter-assay reproducibility.
Similarly, transcript signal intensities were highly
correlated between laboratories across all samples
(median R2 0.984, range 0.960–0.992), consistent with
expectations for inter-assay results.
Discussion
Analytical and clinical validity are important factors in
the evaluation of any new molecular test. The clinical
validity of the Percepta classifier was previously reported as
a useful tool in the clinical evaluation of lung lesions sus-
pected to be cancer [9, 10]. Here we set out to verify the
analytical validity of this test. In addition to salient wet-lab
studies, in silico simulations and modeling were also used
as applicable to establish the validity of test criteria.
The entire process from sample collection, storage,
shipping, sample processing and classification was evalu-
ated. It was demonstrated that nucleic acids extracted
from clinical brushing specimens are stable and yield re-
producible results across a variety of conditions. The
assay was also shown to be robust to routine RNA input
quantity variations.
Analytical specificity was evaluated. From data collected
in the prospective clinical studies, it was shown that rou-
tine clinical samples contain little to no blood content.
Further, in controlled experiments, up to 10 % blood de-
rived RNA showed no impact to the Percepta calls and
scores. The Percepta test also showed robustness to po-
tential contaminating genomic DNA. The RNA extraction
method used in the test demonstrated consistently low
genomic DNA content (<1 %), and up to 10 % genomic
DNA spiked into the starting RNA sample have no detect-
able impact to the Percepta scores.
Analytical reproducibility was evaluated following
technical assessment criteria outlined by EGAPP and
ACCE, using clinical samples with Percepta scores cov-
ering the entire range and concentrated around the deci-
sion boundary of the assay [17]. It has been argued that
accuracy studies for multi-gene molecular tests are often
impossible due to the absence of reference methods
[18]. To establish accuracy of the test offered at the
CLIA-certified laboratory, it was demonstrated with an
inter-laboratory reproducibility study that the results in
this lab are identical to those generated in the laboratory
where the test was developed. When taken together with
the clinical validation studies, the Percepta test success-
fully achieves EGAPP level I analytic validity criteria.
Namely, technical validation involved the extensive use
of well-characterized samples with multiple reference
standard comparison methods including cytopathology,
histopathology, and reference laboratory.
Conclusion
The robustness of the Percepta test to induced variables,
including those that may be encountered in clinical sam-
ples, supports that routine testing of bronchial brushing
specimens can be achieved at high confidence from the
standpoint of analytical performance and reproducibility.
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